Vertex Pharmaceuticals Incorporated VRTX announced today that Health
Canada has approved KALYDECO^TM (ivacaftor), the first medicine to treat the
underlying cause of cystic fibrosis (CF), for people ages 6 and older who have
at least one copy of the G551D mutation in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene. Cystic fibrosis is a rare genetic disease
for which there is no cure. It is caused by a defective or missing CFTR
protein resulting from mutations in the CFTR gene. In people with the G551D
mutation, KALYDECO (kuh-LYE-deh-koh) helps the defective or missing CFTR
protein function more normally. Approximately 100 people in Canada with CF are
believed to have this mutation.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in